Int J Sports Med 2014; 35(09): 800-806
DOI: 10.1055/s-0033-1361185
Review
© Georg Thieme Verlag KG Stuttgart · New York

Implantable Cardioverter Defibrillator in Sport Participation

G. Mascia
1   Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy
4   Cliniche Gavazzeni, Bergamo, Italy
,
L. Di Biase
2   St. David’s Medical Center, Texas Cardiac Arrhythmia Institute, Austin, United States
5   Albert Einstein College of Medicine, Montefiore Hospital, Bronx, NY, United States
7   Department of Biomedical Engineering, University of Texas, Austin, Texas, USA
8   Department of Cardiology, University of Foggia, Foggia, Italy
,
G. Galanti
3   Sports Medicine Department, University of Florence, Florence, Italy
,
A. Natale
2   St. David’s Medical Center, Texas Cardiac Arrhythmia Institute, Austin, United States
6   Division of Cardiology, Stanford University, Palo Alto, California, United States
7   Department of Biomedical Engineering, University of Texas, Austin, Texas, USA
9   California Pacific Medical Center, San Francisco, California, USA
10   Heart and Vascular Center, Case Western Reserve University, Cleveland, Ohio, USA
11   Interventional Electrophysiology, Scripps Clinic, La Jolla, California, USA
,
L. Padeletti
1   Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy
4   Cliniche Gavazzeni, Bergamo, Italy
› Author Affiliations
Further Information

Publication History



accepted after revision 24 October 2013

Publication Date:
15 April 2014 (online)

Abstract

Although athletic participation lowers cardiovascular risk and improves quality of life, it may represent a hazard in high-risk group athletes such as those with cardiac abnormalities receiving an implantable cardioverter defibrillator (ICD). ICD sports participants are exposed to the potential risk of inappropriate shocks due to sinus tachycardia and other supraventricular arrhythmias during exertion as well as device injury. The safety of athletic participation of ICD-patients is not completely defined and ICD efficacy in interrupting malignant arrhythmias during intense exercise is partly unknown. This explains difficulties in current recommendations made by physicians, given the associated potentially ischemic, autonomic and metabolic conditions. The scope of this review is to underline specific considerations including potential risks and recommendations for athletic participation in this patient-group.

 
  • References

  • 1 Almendral J, Arribas F, Wolpert C, Ricci R, Adragao P, Cobo E, Navarro X, Quesada A. Dual-chamber defibrillators reduce clinically significant adverse events compared with single-chamber devices: results from the DATAS trial. Europace 2008; 10: 528-535
  • 2 Anselme F, Mletzko R, Bowes R, Mabo P, Sadoul N, Schoels W, Seidl K, Schwab J, Iscolo N, Nitzsché R. Prevention of inappropriate shocks in ICD recipients: a review of 10,000 tachycardia episodes. Pacing Clin Electrophysiol 2007; 30: 128-133
  • 3 Bansch D, Steffgen F, Gronefeld G, Wolpert C, Bocker D, Mletzko RU, Schols W, Seidl K, Piel M, Ouyang F, Hohnloser SH, Kuck KH. The 1+1trial: a prospective trial of a dual- versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias. Circulation 2004; 110: 1022-1029
  • 4 Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. SCD-HeFT Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237
  • 5 Benito B, Gay-Jordi G, Serrano-Mollar A, Guasch E, Shi Y, Tardif JC, Brugada J, Nattel S, Mont L. Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation 2011; 123: 13-22
  • 6 Berul CI, Van Hare GF, Kertesz NJ, Dubin AM, Cecchin F, Collins KK, Cannon BC, Alexander ME, Triedman JK, Walsh EP, Friedman RA. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol 2008; 51: 1685-1691
  • 7 Blair SN, Kohl 3rd HW, Paffenbarger Jr RS, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 1989; 262: 2395-2401
  • 8 Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. COMPANION Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150
  • 9 Brugada J, Mont L, Figueiredo M, Valentino M, Matas M, Navarro-Lopez F. Enhanced detection criteria in implantable defibrillators. J Cardiovasc Electrophysiol 1998; 9: 261-268
  • 10 Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341: 1882-1890
  • 11 Celiker A, Kafali G, Dogan R. Cardioverter defibrillator implantation in a child with isolated noncompaction of the ventricular myocardium and ventricular fibrillation. Pacing Clin Electrophysiol 2004; 27: 104-108
  • 12 Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitchell LB, Green MS, Klein GJ, O’Brien B. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297-1302
  • 13 Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, Boczor S, Domanski M, Follmann D, Gent M, Roberts RS. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21: 2071-2078
  • 14 Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults?. J Am Coll Cardiol 2003; 42: 1959-1963
  • 15 Corrado D, Basso C, Thiene G. Essay: sudden death in young athletes. Lancet 2005; 366: S47-S48
  • 16 Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, Basso C, Ward D, Boriani G, Ricci R, Piccini JP, Dalal D, Santini M, Buja G, Iliceto S, Estes 3rd NA, Wichter T, McKenna WJ, Thiene G, Marcus FI. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation 2010; 122: 1144-1152
  • 17 Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, Salerno JU, Igidbashian D, Raviele A, Disertori M, Zanotto G, Verlato R, Vergara G, Delise P, Turrini P, Basso C, Naccarella F, Maddalena F, Estes 3rd NA, Buja G, Thiene G. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003; 108: 3084-3091
  • 18 Corrado D, Thiene G, Nava A, Rossi L, Pennelli N. Sudden death in young competitive athletes: clinicopathologic correlations in 22 cases. Am J Med 1990; 89: 588-596
  • 19 Deisenhofer I, Kolb C, Ndrepepa G, Schreieck J, Karch M, Schmieder S, Zrenner B, Schmitt C. Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies? A randomized, prospective study. J Cardiovasc Electrophysiol 2001; 12: 134-142
  • 20 Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004; 292: 2874 -2879
  • 21 Epstein AE, DiMarco JP, Ellenbogen KA, Estes 3rd NA, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2013; 61: e6-e75
  • 22 Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med 2003; 138: 445-452
  • 23 Fogel RI. Athletes and ICDs: What to Do When the Clinical Community Disagrees with the “Experts”. J Cardiovasc Electrophysiol 2006; 17: 16-17
  • 24 Friedman PA, McClelland RL, Bamlet WR, Acosta H, Kessler D, Munger TM, Kavesh NG, Wood M, Daoud E, Massumi A, Schuger C, Shorofsky S, Wilkoff B, Glikson M. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the Detect Supraventricular Tachycardia (DETECT SVT) study. Circulation 2006; 113: 2871-2879
  • 25 Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, Hersi A, Gulaj M, Wijfels MC, Santi E, Manotta L, Arenal A. Effect of long-detection interval vs. standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA 2013; 309: 1903-1911
  • 26 Gunderson BD, Gillberg JM, Wood MA, Vijayaraman P, Shepard RK, Ellenbogen KA. Development and testing of an algorithm to detect implantable cardioverter-defibrillator lead failure. Heart Rhythm 2006; 3: 155-162
  • 27 Hassmen P, Koivula N, Uutela A. Physical exercise and psychological well-being: a population study in Finland. Prev Med 2000; 30: 17-25
  • 28 Heidbuchel H. Implantable cardioverter defibrillator therapy in athletes. Cardiol Clin 2007; 25: 467-482
  • 29 Heidbüchel H, Corrado D, Biffi A, Hoffmann E, Panhuyzen-Goedkoop N, Hoogsteen J, Delise P, Hoff PI, Pelliccia A. Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part II: ventricular arrhythmias, channelopathies and implantable defibrillators. Eur J Cardiovasc Prev Rehabil 2006; 13: 676-686
  • 30 Heidbüchel H, Hoogsteen J, Fagard R, Vanhees L, Ector H, Willems R, Van Lierde J. High prevalence of right ventricular involvement in endurance athletes with ventricular arrhythmias: role of an electrophysiologic study in risk stratification. Eur Heart J 2003; 24: 1473-1480
  • 31 Hodgkinson KA, Parfrey PS, Bassett AS, Kupprion C, Drenckhahn J, Norman MW, Thierfelder L, Stuckless SN, Dicks EL, McKenna WJ, Connors SP. The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol 2005; 45: 400-408
  • 32 Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH. DEFINITE Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-2158
  • 33 Karjalainen J, Kujala UM, Kaprio J, Sarna S, Viitasalo M. Lone atrial fibrillation in vigorously exercising middle aged men: case-control study. BMJ 1998; 316: 1784-1785
  • 34 Klein GJ, Gillberg JM, Tang A, Inbar S, Sharma A, Unterberg-Buchwald C, Dorian P, Moore H, Duru F, Rooney E, Becker D, Schaaf K, Benditt D. Improving SVT discrimination in single-chamber ICDs: a new electrogram morphology-based algorithm. J Cardiovasc Electrophysiol 2006; 17: 1310-1319
  • 35 Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, Sugawara A, Totsuka K, Shimano H, Ohashi Y, Yamada N, Sone H. Cardiorespiratory fitness as a quantitative predictor of all-causemortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA 2009; 301: 2024-2035
  • 36 Koneru JN, Swerdlow CD, Wood MA, Ellenbogen KA. Minimizing inappropriate or “unnecessary” implantable cardioverter-defibrillator shocks: appropriate programming. Circ Arrhythm Electrophysiol 2011; 4: 778-790
  • 37 Krip B, Gledhill N, Jamnik V, Warburton D. Effect of alterations in blood volume on cardiac function during maximal exercise. Med Sci Sports Exerc 1997; 29: 1469-1476
  • 38 Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748-754
  • 39 Kuhlkamp V, Dornberger V, Mewis C, Suchalla R, Bosch RF, Seipel L. Clinical experience with the new detection algorithms for atrial fibrillation of a defibrillator with dual chamber sensing and pacing. J Cardiovasc Electrophysiol 1999; 10: 905-915
  • 40 La Gerche A, Burns AT, Mooney DJ, Inder WJ, Taylor AJ, Bogaert J, Macisaac AI, Heidbuchel H, Prior DL. Exercise-induced right ventricular dysfunction and structural remodelling in endurance athletes. Eur Heart J 2012; 33: 998-1006
  • 41 Lampert R, Cannom D. Sports participation for athletes with implantable cardioverter-defibrillators should be an individualized risk–benefit decision. Heart Rhythm 2008; 5: 861-863
  • 42 Lampert R, Cannom D, Olshansky B. Safety of Sports Participation in Patients with Implantable Cardioverter Defibrillators: A Survey of Heart Rhythm Society Members. J Cardiovasc Electrophysiol 2006; 17: 11-15
  • 43 Lampert R, Olshansky B, Heidbuchel H, Lawless C, Saarel E, Ackerman M, Calkins H, Estes NA, Link MS, Maron BJ, Marcus F, Scheinman M, Wilkoff BL, Zipes DP, Berul CI, Cheng A, Law I, Loomis M, Barth C, Brandt C, Dziura J, Li F, Cannom D. Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators: Results of a Prospective, Multinational Registry. Circulation 2013; 127: 2021-2030
  • 44 Law IH, Shannon K. Implantable cardioverter-defibrillators and the young athlete: can the two coexist?. Pediatr Cardiol 2012; 33: 387-393
  • 45 Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7 – year follow-up of 21 patients. Circulation 1995; 91: 1512-1519
  • 46 Maron BJ. Sudden death in young athletes. N Engl J Med 2003; 349: 1064-1075
  • 47 Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009; 119: 1085-1092
  • 48 Maron BJ, Mitten MJ, Quandt EF, Zipes DP. Competitive athletes with cardiovascular disease: the case of Nicholas Knapp. N Engl J Med 1998; 339: 1632-1635
  • 49 Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes 3rd NA, Spirito P. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 365-373
  • 50 Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996; 276: 199-204
  • 51 Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes 3rd NA, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Implantable cardioverter defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298: 405-412
  • 52 Maron BJ, Zipes DP. 36th Bethesda Conference: eligibility recommendations for competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol 2005; 45: 1312-1375
  • 53 Maron BJ, Zipes DP. It is not prudent to allow all athletes with implantable cardioverter defibrillators to participate in all sports. Heart Rhythm 2008; 5: 864-866
  • 54 Matsuo K, Kurita T, Inagaki M, Kakishita M, Aihara N, Shimizu W, Taguchi A, Suyama K, Kamakura S, Shimomura K. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J 1999; 20: 465-470
  • 55 Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, Langer A, Heilman MS, Kolenik SA, Fischell RE, Weisfeldt ML. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980; 303: 322-324
  • 56 Mönnig G, Köbe J, Löher A, Eckardt L, Wedekind H, Scheld HH, Haverkamp W, Milberg P, Breithardt G, Schulze-Bahr E, Böcker D. Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. Heart Rhythm 2005; 2: 497-504
  • 57 Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933-1940
  • 58 Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, Estes 3rd NA, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S, Olshansky B, Shoda M, Wilber D, Zareba W. MADIT-RIT Trial Investigators . Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012; 367: 2257-2283
  • 59 Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883
  • 60 Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004; 44: 2166 -2172
  • 61 Pelliccia A, Fagard R, Bjørnstad HH, Anastassakis A, Arbustini E, Assanelli D, Biffi A, Borjesson M, Carrè F, Corrado D, Delise P, Dorwarth U, Hirth A, Heidbuchel H, Hoffmann E, Mellwig KP, Panhuyzen-Goedkoop N, Pisani A, Solberg EE, van-Buuren F, Vanhees L, Blomstrom-Lundqvist C, Deligiannis A, Dugmore D, Glikson M, Hoff PI, Hoffmann A, Hoffmann E, Horstkotte D, Nordrehaug JE, Oudhof J, McKenna WJ, Penco M, Priori S, Reybrouck T, Senden J, Spataro A, Thiene G. Recommendations for competitive sports participation in athletes with cardiovascular disease. A Consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology, and the Working Group of Myocardial and Pericardial diseases of the European Society of Cardiology. Eur Heart J 2005; 26: 1422-1445
  • 62 Pelliccia A, Zipes DP, Maron BJ. Bethesda Conference #36 and the European Society of Cardiology Consensus Recommendations Revisited A Comparison of U.S. and European Criteria for Eligibility and Disqualification of Competitive Athletes With Cardiovascular Abnormalities. J Am Coll Cardiol 2008; 52: 1990-1996
  • 63 Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348: 1866-1874
  • 64 Sarkozy A, Boussy T, Kourgiannides G, Chierchia GB, Richter S, De Potter T, Geelen P, Wellens F, Spreeuwenberg MD, Brugada P. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J 2007; 28: 334-344
  • 65 Saxon LA, Hayes DL, Gilliam FR, Heidenreich PA, Day J, Seth M, Meyer TE, Jones PW, Boehmer JP. Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation 2010; 122: 2359-2367
  • 66 Schaumann A, von zur Mühlen F, Herse B, Gonska BD, Kreuzer H. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: a prospective study including 200 patients. Circulation 1998; 97: 66-74
  • 67 Sousa J, Kou W, Calkins H, Rosenheck S, Kadish A, Morady F. Effect of epinephrine on the efficacy of the internal cardioverter-defibrillator. Am J Cardiol 1992; 69: 509-512
  • 68 Srivathsan K, Scott LR, Altemose GT. T-wave oversensing and inappropriate shocks: a case report. Europace 2008; 10: 552-555
  • 69 Stene M, Panagiotis N, Tuck ML, Sowers JR, Mayes D, Berg G. Plasma norepinephrine levels are influenced by sodium intake, glucocorticoid administration, and circadian changes in normal man. J Clin Endocrinol Metab 1980; 50: 1340-1345
  • 70 Suddath WO, Deychak Y, Varghese PJ. Electrophysiologic basis by which epinephrine facilitates defibrillation after prolonged episodes of ventricular fibrillation. Ann Emerg Med 2001; 38: 201-206
  • 71 Swerdlow CD, Gunderson BD, Ousdigian KT, Abeyratne A, Sachanandani H, Ellenbogen KA. Downloadable Software Algorithm Reduces Inappropriate Shocks Caused by Implantable Cardioverter-Defibrillator Lead Fractures. A Prospective Study. Circulation 2010; 122: 1449-1455
  • 72 Swerdlow CD, Shehata M. Antitachycardia pacing in primary-prevention ICDs. J Cardiovasc Electrophysiol 2010; 21: 1355-1357
  • 73 The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators . A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-1583
  • 74 Theuns DA, Klootwijk AP, Goedhart DM, Jordaens LJ. Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms. J Am Coll Cardiol 2004; 44: 2362-2367
  • 75 Trivax JE, Franklin BA, Goldstein JA, Chinnaiyan KM, Gallagher MJ, deJong AT, Colar JM, Haines DE, McCullough PA. Acute cardiac effects of marathon running. J Appl Physiol 2010; 108: 1148-1153
  • 76 Trivax JE, McCullough PA. Phidippides Cardiomyopathy: A Review and Case Illustration. Clin Cardiol 2012; 35: 69-73
  • 77 Venditti Jr FJ, John RM, Hull M, Tofler GH, Shahian DM, Martin DT. Circadian variation in defibrillation energy requirements. Circulation 1996; 94: 1607-1612
  • 78 Volosin KJ, Exner DV, Wathen MS, Sherfesee L, Scinicariello AP, Gillberg JM. Combining shock reduction strategies to enhance ICD therapy: a role for computer modeling. J Cardiovasc Electrophysiol 2011; 22: 280-289
  • 79 Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, Khalighi K, Machado C, Rubenstein DS, Volosin KJ. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 2004; 110: 2591-2596
  • 80 Wathen MS, Sweeney MO, DeGroot PJ, Stark AJ, Koehler JL, Chisner MB, Machado C, Adkisson WO. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 2001; 104: 796-801
  • 81 Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol 2006; 48: 330-339
  • 82 Wilkoff B, Williamson B, Stern R, Moore S, Lu F, Lee S, Birgersdotter-Green U, Wathen M, Van Gelder I, Heubner B, Brown M, Holloman K. Strategic programming of detection and therapy parameters in implantable defibrillators reduces shocks in primary prevention patients: results from the PREPARE study. J Am Coll Cardiol 2008; 52: 541-550
  • 83 Zareb W, Moss AJ, Daubert JP, Hall WJ, Robinson JL, Andrews M. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol 2003; 14: 337-341
  • 84 Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Smith Jr SC, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. J Am Coll Cardiol 2006; 48: e247-e346